Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 15/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.88 |
| ▸ | JAK3 | P52333 | 1/20 | 0.88 |
| ▸ | BTK | Q06187 | 1/20 | 0.88 |
| ▸ | ITK | Q08881 | 1/20 | 0.88 |
| ▸ | KDR | P35968 | 4/20 | 0.82 |
| ▸ | ABL1 | P00519 | 8/20 | 0.80 |
| ▸ | BCR | P11274 | 6/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.80 |
| ▸ | PRKCA | P17252 | 1/20 | 0.79 |
| ▸ | KIT | P10721 | 7/20 | 0.79 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.76 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.76 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.76 |
| ▸ | ABL2 | P42684 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927817 | 0.96 | PDGFRA (0.92) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL5050327 | 0.94 | PDGFRA (0.89) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL2229310 | 0.94 | EGFR (1.00) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL11927826 | 0.93 | PDGFRA (0.87) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL11927811 | 0.92 | PDGFRA (0.85) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL11927767 | 0.91 | PDGFRA (0.83) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL14979770 | 0.90 | PDGFRA (0.82) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL3636349 | 0.90 | PDGFRA (1.00) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL11927812 | 0.90 | PDGFRA (1.00) | PDGFRAEGFRJAK3BTKITK | |
| SCHEMBL4803395 | 0.89 | PDGFRA (0.87) | PDGFRAEGFRKDRABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8586600-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010028236-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028236-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-2152079-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885EGFR 2849/4885JAK3 741/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885EGFR 2849/4885JAK3 741/4885 |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885EGFR 2849/4885JAK3 741/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | PDGFRA 3647/4885EGFR 1023/4885JAK3 2385/4885 |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885EGFR 2849/4885JAK3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.